SK6172000A3 - Use of macrolides for the treatment of cancer and macular degeneration - Google Patents

Use of macrolides for the treatment of cancer and macular degeneration Download PDF

Info

Publication number
SK6172000A3
SK6172000A3 SK617-2000A SK6172000A SK6172000A3 SK 6172000 A3 SK6172000 A3 SK 6172000A3 SK 6172000 A SK6172000 A SK 6172000A SK 6172000 A3 SK6172000 A3 SK 6172000A3
Authority
SK
Slovakia
Prior art keywords
substituted
heteroaryl
defined above
alkyl
group
Prior art date
Application number
SK617-2000A
Other languages
English (en)
Slovak (sk)
Inventor
Yat Sun Or
Jacob J Plattner
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of SK6172000A3 publication Critical patent/SK6172000A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
SK617-2000A 1997-10-31 1998-10-30 Use of macrolides for the treatment of cancer and macular degeneration SK6172000A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96147397A 1997-10-31 1997-10-31
PCT/US1998/023043 WO1999022722A2 (fr) 1997-10-31 1998-10-30 Utilisation de macrolides pour le traitement du cancer et de la degenerescence maculaire

Publications (1)

Publication Number Publication Date
SK6172000A3 true SK6172000A3 (en) 2001-03-12

Family

ID=25504514

Family Applications (1)

Application Number Title Priority Date Filing Date
SK617-2000A SK6172000A3 (en) 1997-10-31 1998-10-30 Use of macrolides for the treatment of cancer and macular degeneration

Country Status (17)

Country Link
EP (1) EP1027060A2 (fr)
JP (1) JP2001521891A (fr)
KR (1) KR20010031577A (fr)
CN (1) CN1278178A (fr)
AR (1) AR043071A1 (fr)
AU (1) AU1206799A (fr)
BG (1) BG104436A (fr)
BR (1) BR9813318A (fr)
CA (1) CA2307850A1 (fr)
HU (1) HUP0100012A3 (fr)
IL (1) IL135518A0 (fr)
NO (1) NO20002189L (fr)
PL (1) PL340604A1 (fr)
SK (1) SK6172000A3 (fr)
TR (1) TR200001147T2 (fr)
WO (1) WO1999022722A2 (fr)
ZA (1) ZA989885B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001248588B2 (en) 2000-04-13 2006-02-02 Biotica Technology Limited Hybrid glycosylated products and their production and use
PT1539157E (pt) 2002-09-18 2013-10-04 Univ Pennsylvania Rapamicina para utilização na inibição ou prevenção de neovascularização coroidal
TW200420573A (en) 2002-09-26 2004-10-16 Rib X Pharmaceuticals Inc Bifunctional heterocyclic compounds and methods of making and using same
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
EP1608626A1 (fr) 2003-03-28 2005-12-28 Cornell Research Foundation, Inc. Compositions de substances analogues a la migrastatine et leurs utilisations
US7083802B2 (en) 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
CN102816194A (zh) * 2004-02-27 2012-12-12 瑞伯-X医药品有限公司 大环化合物以及其制作和使用方法
CN1950388A (zh) * 2004-02-27 2007-04-18 瑞伯-X医药品有限公司 大环化合物以及其制作和使用方法
US8957056B2 (en) 2004-05-25 2015-02-17 Sloan-Kettering Instiute For Cancer Research Migrastatin analogs in the treatment of cancer
EP1805161B1 (fr) 2004-09-23 2014-05-07 Sloan-Kettering Institute For Cancer Research Analogues d'isomigrastatine utilises dans le traitement du cancer
EP1848431B1 (fr) 2005-02-09 2016-02-03 Santen Pharmaceutical Co., Ltd. Formulations liquides pour le traitement de maladies ou affections
CA2615990A1 (fr) 2005-07-18 2007-01-25 Minu, L.L.C. Neuro-protection/neuro-stimulation oculaire amelioree
WO2007025284A1 (fr) 2005-08-24 2007-03-01 Rib-X Pharmaceuticals, Inc. Composes de triazole et procedes de fabrication et d'utilisation associes
JP2009506063A (ja) 2005-08-24 2009-02-12 リブ−エックス ファーマシューティカルズ，インコーポレイテッド トリアゾール化合物ならびにこれを作製する方法および使用する方法
WO2007092620A2 (fr) 2006-02-09 2007-08-16 Macusight, Inc. Formulations stables et leurs procedes de preparation et d'utilisation
ES2563288T3 (es) 2006-03-23 2016-03-14 Santen Pharmaceutical Co., Ltd Rapamicina en dosis bajas para el tratamiento de enfermedades relacionadas con la permeabilidad vascular
CN106317146B (zh) * 2015-06-18 2019-06-21 沈阳药科大学 双环克拉霉素衍生物及其作为肿瘤细胞增值抑制剂的用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6461090A (en) * 1989-10-30 1991-05-02 Abbott Laboratories Injectable formulation for lipophilic drugs
US5498424A (en) * 1994-11-30 1996-03-12 Klein; Ira Method of treating obesity

Also Published As

Publication number Publication date
PL340604A1 (en) 2001-02-12
NO20002189L (no) 2000-06-28
HUP0100012A2 (hu) 2001-05-28
TR200001147T2 (tr) 2000-08-21
AU1206799A (en) 1999-05-24
CA2307850A1 (fr) 1999-05-14
BG104436A (en) 2000-12-29
WO1999022722A3 (fr) 1999-08-05
WO1999022722A2 (fr) 1999-05-14
IL135518A0 (en) 2001-05-20
HUP0100012A3 (en) 2003-07-28
EP1027060A2 (fr) 2000-08-16
KR20010031577A (ko) 2001-04-16
JP2001521891A (ja) 2001-11-13
CN1278178A (zh) 2000-12-27
ZA989885B (en) 1999-05-05
NO20002189D0 (no) 2000-04-27
BR9813318A (pt) 2000-08-22
AR043071A1 (es) 2005-07-20

Similar Documents

Publication Publication Date Title
SK6172000A3 (en) Use of macrolides for the treatment of cancer and macular degeneration
AU2014203882B2 (en) Methods for reducing cellular proliferation and treating certain diseases
EP0929563B1 (fr) Cetolides substitues en 6-o possedant une activite antibacterienne
EP1928470A2 (fr) Modulateurs du facteur 1 induit par hypoxie et utilisations associees dans le traitement de troubles oculaires
JP2000505469A (ja) 新規なエリスロマイシン誘導体、それらの調製方法及びそれらの医薬品としての使用
EA016653B1 (ru) Способы и композиции для ингибирования ангиогенеза
KR20140139083A (ko) 마크롤라이드계 항생제를 투여하기 위한 비경구 제제
JP2836964B2 (ja) １６員環マクロライド系抗生物質の誘導体
KR0179379B1 (ko) 4"-데옥시에리트로마이신 유도체
EP1025114B1 (fr) Derives d'erythromycine cetolides, modifies en n-3' et substitues en o-6, possedant une activite antibacterienne
CN1269803A (zh) 6,9－桥红霉素衍生物
EP1167375A1 (fr) Derives d'erythromycine
JPH07110874B2 (ja) エリスロマイシンａ誘導体
JP2003507487A (ja) 抗菌活性を有する９ａ−アザライド類
JP2004529921A (ja) ロイコマイシンから誘導された９−アミノ−１４員環マクロライド
CZ20001524A3 (cs) Farmaceutický přípravek pro léčení nádorů a makulární degenerace
KR20200014880A (ko) 테세탁셀 및 카페시타빈에 대한 투약 일정
WO2013132014A1 (fr) Dérivés semi-synthétiques de nystatine a1
EP1259923B1 (fr) Agents anti-infectieux utiles contre des souches de bacteries resistant a l'action de plusieurs medicaments
JP2001518475A (ja) 環状亜リン酸およびリン酸塩
JPH06507407A (ja) エリスロマイシン誘導体
JP2020509086A (ja) トリアゾール含有マクロライド及びその眼科的使用
JP2020511445A (ja) ドライアイ疾患を治療するための組成物および方法
JPH08512324A (ja) エリスロマイシン誘導体
CN118078793A (zh) Gw3965在制备减轻阿霉素心脏损伤的药物中的应用